London Launches £10M Cardiometabolic Innovation Programme for NHS

The Frontier Innovation for Cardiometabolic Disease Programme has launched in London backed by the Mayor of London and £10 million via the Local Innovation Partnerships Fund of UK Research and Innovation, to move heart disease, diabetes, and obesity digital health tools, medical devices, and therapeutics from research into NHS and private care, according to The Medical News and Healthcare Management Magazine. In the UK, promising health technologies often stall before reaching patients because companies struggle to collect the real-world evidence required by healthcare providers, The Medical News reported.
Two £5 Million Tracks and Clinical Partners
The initiative is split into two £5 million programmes: Venture Builder and Validate and Scale, according to The Medical News. Venture Builder will help create and expand more than 30 startups developing therapeutics via the Novo Nordisk Foundation-backed BioInnovation Institute and medical technologies, aiming to launch four to six clinical trials and draw £200 million in private investment, The Medical News reported. Validate and Scale pairs private healthcare providers with the NHS, led by UCLPartners with Health Innovation Network South London, Imperial College Health Partners, and the Harley Street Health District, to test solutions in real clinical settings, according to The Medical News. Validate and Scale aims to engage over 100 companies, give tailored backing to at least 20, and help at least five breakout-stage firms validate and scale in London while leveraging £50 million to £100 million in private funding, The Medical News reported.
Prevention Priorities, Jobs, and Leadership Remarks
Across both tracks, partners aim to attract up to £300 million in private investment and generate up to 1,000 high-value jobs in London, while London's three health innovation networks spread proven tools across NHS services, The Medical News reported. Programme priorities span the full cardiometabolic prevention pathway, from earlier risk identification to lifestyle support and ongoing management of conditions such as high blood pressure, according to The Medical News. Deputy Mayor of London for Business and Growth Howard Dawber said the collaboration can pioneer new technologies and treatments, potentially saving lives for thousands of Londoners while strengthening the life sciences sector, Healthcare Management Magazine reported. NHS England London Regional Director of Public Health Professor Kevin Fenton noted that cardiovascular disease causes one in four deaths in London, hitting the most deprived communities hardest, The Medical News reported. The Medical News added that BioInnovation Institute is supported by the Novo Nordisk Foundation and ranks among Europe's leading innovation institutes.
Background
City Hall projects that targeted improvements in hypertension treatment in London could prevent over 1,200 heart attacks and save the NHS around £46m and social care services £12m, according to Greater London Authority (London City Hall).
Since its establishment, BioInnovation Institute (BII) has supported more than 140 companies that have collectively attracted significant external capital, according to Drug Discovery World (DDW).
BioInnovation Institute (BII) is providing a total of around €9.5 million to 17 new companies, according to Drug Discovery World (DDW).
London’s total Local Innovation Partnerships Fund allocation is £30m with the remainder of the funds to be allocated in due course, according to Greater London Authority (London City Hall).
